Vor Bio appoints Blueprint R&D President Fouad Namouni to Board of Directors

Vor Biopharma Inc.

Appointed independent Class II director effective April 30, 2024; term until 2026 annual meeting.
Dr. Namouni has over 20 years oncology drug development; currently President of R&D at Blueprint Medicines.
Receives standard non-employee director compensation: $40,000 cash retainer plus 60,000 stock option.
Company highlights his experience in cell/genome engineering for acute myeloid leukemia pipeline.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Fouad Namouni

Director

VOR · Vor Biopharma Inc.

Effective: 2024-04-30
Filed: May 2, 2024, 7:59 PM ET

On April 30, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) increased the size of the Board from six to seven members and appointed Fouad Namouni, M.D., to fill the resulting vacancy, to serve on the Board as an independent Class II director, until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fouad Namouni was appointed as Director at Vor Biopharma Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 30, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) increased the size of the Board from six to seven members and appointed Fouad Namouni, M.D., to fill the resulting vacancy, to serve on the Board as an independent Class II director, until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified.

View on SEC.gov

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-129357

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.